Placing a medical device on the European market requires a clear, evidence-based demonstration of biological safety, as defined by the MDR (EU 2017/745) and the ISO 10993 series. Sobel supports companies with biological evaluation Europe, transforming regulatory expectations into structured strategies, compliant documentation, and defensible regulatory outcomes.
A well-structured biological evaluation is mandatory to support CE marking and ensure patient safety throughout the product lifecycle.
The MDR and ISO 10993 require manufacturers to demonstrate that their medical devices do not present unacceptable biological risks, based on a structured, risk-based evaluation.
Without a clear biological evaluation strategy, data gaps and weak justifications often emerge during Notified Body review, leading to delays and additional requests.
This service helps you define a defensible biological evaluation pathway that supports compliance, protects patients, and enables smoother access to the European market.
Biological evaluation requirements vary by device risk, body contact, and available data. Sobel helps you structure and document a risk-based biological evaluation aligned with European regulatory expectations.
At Sobel, you can request a combined BEP + BER solution, as well as complementary biological and strategic support.
An end-to-end biological evaluation solution, covering both planning and final reporting. This combined service is ideal for manufacturers seeking a complete, consistent biological evaluation pathway aligned with MDR requirements—from strategy definition to submission-ready documentation.
Identification and analysis of gaps between available data and MDR/ISO 10993 expectations. This service supports manufacturers in understanding data completeness, relevance, and suitability before proceeding with risk assessment, testing, or document updates.
Preparation of a standalone Biological Risk Assessment, based on toxicological parameters and available data provided by the manufacturer. This service focuses on critical biological risk analysis to support regulatory decision-making.
Preparation of a toxicological assessment based on chemical characterization data (extractables and/or leachables) to evaluate potential risks related to substances released from a medical device. This service supports the biological evaluation under the EU MDR and ISO 10993 series.
Focused regulatory support for specific biological evaluation challenges, including strategy definition and expert input for complex or unclear situations. This service is particularly useful when addressing Notified Body questions, deficiencies, or internal uncertainties related to biological safety.
If you are unsure which biological evaluation service is the right fit, Sobel’s experts can support you in defining the most suitable regulatory pathway.
Biological evaluation is often part of a broader regulatory pathway, and the services below may support related compliance activities:
Internal audits supporting ISO 13485 compliance and notified body readiness in Europe.
Gap analysis, technical documentation, and ongoing regulatory for CE Mark for Medical Devices.
Quality management support, aligned with EU MDR and ISO 13485 requirements.
Strong biological evaluation is essential for CE marking and long-term regulatory success in Europe. Sobel helps manufacturers navigate ISO 10993 and MDR requirements with clarity, structure, and confidence—transforming complex biological safety expectations into manageable, compliant steps.
1. Is biological evaluation mandatory for all medical devices in Europe?
Yes. All medical devices placed on the European market must demonstrate biological safety in accordance with the EU MDR (2017/745) and the ISO 10993 series. The scope and depth of the biological evaluation depend on the device classification, nature and duration of body contact, and available data.
2. What is the difference between a BEP and a BER?
The Biological Evaluation Plan (BEP) defines the evaluation strategy, applicable standards, and required data. The Biological Evaluation Report (BER) documents the critical analysis of available evidence and supports conclusions on biological safety. Both documents play complementary roles under EU MDR.
3. Do Class I devices also require biological evaluation?
Yes. Even Class I devices must demonstrate biological safety. While the evaluation is generally less complex, it still requires a documented, risk-based justification aligned with ISO 10993-1.
4. Does biological evaluation always require laboratory testing?
Not necessarily. Biological evaluation is a risk-based process. Depending on the device and available evidence, literature data, material characterization, and equivalence arguments may be sufficient. Sobel’s experts assess the available data and guide manufacturers on whether biological testing is necessary, recommending additional tests only when existing evidence is incomplete or insufficient to support biological safety conclusions.
5. Can Sobel review biological evaluation documents prepared by our internal team or a third party?
Yes. Sobel provides critical review and revision services for BEPs and BERs prepared by manufacturers or external consultants, offering expert feedback while maintaining manufacturer ownership of the documentation.
Subscribe to our newsletter to receive the latest updates and insights.
You may unsubscribe at any time using the link in our newsletter.